Cipla announced the launch of Methenamine Hippurate, a non-antibiotic treatment for individuals experiencing recurrent urinary tract infections (UTIs), branded as HUENA. In India, UTIs are the second most frequent cause of antibiotic prescriptions, with infection rates having doubled in the past three decades. The company noted that women are particularly vulnerable to UTIs, which represent 15 percent of all antibiotic prescriptions.
